Athersys

Business model

Clinical-stage biotech developing MultiStem, a stem-cell therapy for ischemic stroke and other conditions.

In brief

Spent nearly three decades developing MultiStem, a stem-cell therapy aimed at treating ischemic stroke, one of the leading causes of long-term disability worldwide. An interim analysis of its Phase 3 trial revealed the study had not enrolled enough patients to reliably meet its p…

See the What Happened tab for the full account.